Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Oral Health

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 3 · 75%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Number of days in hospital · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
MD 0.00 [-1.64, 1.64]
1 study · 281 participants
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Number of days unable to take medicine orally · Adults with cancer receiving treatment

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
No studies reported this outcome (planned secondary outcome not measured by any study in the review)
0 studies
No studies found

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Interruptions to cancer treatment (unscheduled radiotherapy breaks of 5 or more days) · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (unscheduled radiotherapy breaks… compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck with cisplatin/fluorouracil
RR 1.01 [0.65, 1.59]
3 studies · 473 participants
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days of treatment with opioid analgesics compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
MD -1.41 [-3.33, 0.51]
2 studies · 323 participants
GRADE not reported